Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Clinical and histopathological predictors of outcome in malignant meningioma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Despite extensive treatment, overall survival (OS) for glioblastoma (GBM) remains poor. A small proportion of patients present long survival over 3 years, but the underlying molecular background separating these long-term survivors (LTS) from short-term survivors (STS) are insufficiently understood. Accordingly, study aim was to identify independent prognostic biomarkers for survival. Study cohort consisted of 93 primary GBM patients treated with radiation-, chemo- and bevacizumab therapy, among which 14 STS (OS ≤ 12 months) and 6 LTS (OS ≥ 36 months) were identified, all confirmed being IDH wild-type. RNA expression levels in diagnostic tumor specimen for 792 genes were analyzed by NanoString technology. While no differences were found with regard to GBM subtype between LTS versus STS, comparative analysis of individual genes identified 14 significantly differently expressed candidate genes. Univariate analysis in the whole patient cohort found that 12 of these were significantly associated with OS, of which increased IFNG, CXCL9, LGALS4, CD34 and decreased MGMT levels remained significant associated with prolonged OS in multivariate analysis correcting for known prognostic variables. Validation analyses in an independent dataset from the AVAglio study confirmed CD34 as significant in comparative analysis between STS and LTS patients and as an independent prognostic factor. Analysis of this dataset further supported CD34 expression to be associated with improved bevacizumab efficacy, while CD34 immunohistochemistry indicated variation in CD34 expression to result primarily from varying tumor vascularization. Collectively, CD34 expression candidates as a prognostic biomarker in GBM able to identify survival outliers and could also be predictive for efficacy of bevacizumab.

Original languageEnglish
JournalJournal of Neuro-Oncology
Volume137
Issue number3
Pages (from-to)533-542
Number of pages10
ISSN0167-594X
DOIs
Publication statusPublished - May 2018

ID: 55351288